Prognostic role of systemic inflammation response index in patients with non-small cell lung cancer: a meta-analysis.

IF 2.4 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

BMJ Open Pub Date : 2024-11-12 DOI:10.1136/bmjopen-2024-087841

Xingchen Ye, Menglu Dai, Zhuofang Xiang

{"title":"Prognostic role of systemic inflammation response index in patients with non-small cell lung cancer: a meta-analysis.","authors":"Xingchen Ye, Menglu Dai, Zhuofang Xiang","doi":"10.1136/bmjopen-2024-087841","DOIUrl":null,"url":null,"abstract":"Objectives: The significance of the systemic inflammation response index (SIRI) for predicting prognostic outcomes in patients with non-small cell lung cancer (NSCLC) has been analysed in previous studies, but no consistent conclusions have been obtained. Consequently, the present meta-analysis was performed to identify the significance of SIRI in predicting the prognosis of NSCLC.Design: This study followed the PRISMA guidelines.Data sources: PubMed, Web of Science and Embase databases were searched between their inception and 26 November 2023.Eligibility criteria for selecting studies: Studies investigating the relationship between SIRI and survival outcomes of patients with NSCLC were included.Data extraction and synthesis: The value of SIRI in predicting prognosis in NSCLC cases was predicted using combined hazard ratios (HRs) and 95% CIs.Results: Nine articles with 3728 cases were enrolled in this study. Based on our combined data, a higher SIRI value was markedly linked with poor overall survival (OS) (HR=2.08, 95% CI 1.68 to 2.58, p<0.001) and inferior progression-free survival (PFS) (HR=1.74, 95% CI 1.47 to 2.07, p<0.001) of NSCLC. According to the subgroup analysis, country, history and cut-off value did not affect the significance of SIRI in predicting OS and PFS in NSCLC (p<0.05).Conclusions: A higher SIRI value was significantly associated with both OS and PFS in patients with NSCLC. Moreover, SIRI had a stable prognostic efficiency for NSCLC in various subgroups.","PeriodicalId":9158,"journal":{"name":"BMJ Open","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjopen-2024-087841","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The significance of the systemic inflammation response index (SIRI) for predicting prognostic outcomes in patients with non-small cell lung cancer (NSCLC) has been analysed in previous studies, but no consistent conclusions have been obtained. Consequently, the present meta-analysis was performed to identify the significance of SIRI in predicting the prognosis of NSCLC.

Design: This study followed the PRISMA guidelines.

Data sources: PubMed, Web of Science and Embase databases were searched between their inception and 26 November 2023.

Eligibility criteria for selecting studies: Studies investigating the relationship between SIRI and survival outcomes of patients with NSCLC were included.

Data extraction and synthesis: The value of SIRI in predicting prognosis in NSCLC cases was predicted using combined hazard ratios (HRs) and 95% CIs.

Results: Nine articles with 3728 cases were enrolled in this study. Based on our combined data, a higher SIRI value was markedly linked with poor overall survival (OS) (HR=2.08, 95% CI 1.68 to 2.58, p<0.001) and inferior progression-free survival (PFS) (HR=1.74, 95% CI 1.47 to 2.07, p<0.001) of NSCLC. According to the subgroup analysis, country, history and cut-off value did not affect the significance of SIRI in predicting OS and PFS in NSCLC (p<0.05).

Conclusions: A higher SIRI value was significantly associated with both OS and PFS in patients with NSCLC. Moreover, SIRI had a stable prognostic efficiency for NSCLC in various subgroups.

查看原文本刊更多论文

非小细胞肺癌患者全身炎症反应指数的预后作用：一项荟萃分析。

研究目的既往研究分析了全身炎症反应指数（SIRI）对预测非小细胞肺癌（NSCLC）患者预后的意义，但未得出一致结论。因此，本研究进行了荟萃分析，以确定 SIRI 在预测 NSCLC 预后方面的意义：本研究遵循 PRISMA 指南：数据来源：对PubMed、Web of Science和Embase数据库从开始到2023年11月26日期间的数据进行了检索：纳入调查SIRI与NSCLC患者生存结果之间关系的研究：使用综合危险比（HRs）和95%CIs预测SIRI在预测NSCLC病例预后中的价值：本研究共收录了 9 篇文章，涉及 3728 个病例。根据我们的综合数据，SIRI 值越高，总生存率（OS）越低（HR=2.08，95% CI 1.68 至 2.58，pConclusions：较高的SIRI值与NSCLC患者的OS和PFS均有显著相关性。此外，SIRI对不同亚组的NSCLC具有稳定的预后效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ Open MEDICINE, GENERAL & INTERNAL-

CiteScore

4.40

自引率

3.40%

发文量

4510

审稿时长

2-3 weeks

期刊介绍： BMJ Open is an online, open access journal, dedicated to publishing medical research from all disciplines and therapeutic areas. The journal publishes all research study types, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Publishing procedures are built around fully open peer review and continuous publication, publishing research online as soon as the article is ready.